According to a new report, published by KBV research, The Global Transcatheter Aortic Valve Replacement Market size is expected to reach $8 billion by 2028, rising at a market growth of 7.5% CAGR during the forecast period.
The Cobalt-Chromium segment is showcasing a CAGR of 8.3% during (2022 - 2028). The risk of thrombosis is reduced due to its greater radiopacity and robustness when compared to steel stents, which may have a smaller mesh size. Moreover, they have good biocompatibility.
The Transfemoral segment is leading the Global Transcatheter Aortic Valve Replacement Market by Implantation Procedure in 2021 thereby, achieving a market value of $4.2 billion by 2028. The conventional TAVR procedure is described as transfemoral implantation, where the prosthetic valve is inserted through the femoral artery with a little anesthetic. Unfortunately, some individuals cannot have transfemoral TAVR because they have weak or tiny arteries. Transapical implantation, in which the artificial valve is implanted through the left ventricular apex, is favored in this situation.
The Self-expanding Valve segment has shown the growth rate of 8.6% during (2022 - 2028). A greater effective orifice area, fewer gradients, and a lower incidence of severe prosthesis-patient misfit are all benefits of the majority of supra-annular self-expanding valves (PPM). Also, major producers put a lot of effort into new product development, which promotes market expansion.
The Hospitals segment is leading the Global Transcatheter Aortic Valve Replacement Market by End-use in 2021 thereby, achieving a market value of $6.9 billion by 2028. Most facilities where complex and cutting-edge surgical operations are performed are hospitals. Cardiologists, or doctors specializing in cardiac operations, typically do TAVR in a hospital setting. Before TAVR, the medical personnel will measure the valve opening. Then they will administer sedatives or tranquilizers to the patients and drugs to prevent potentially lethal blood clots.
The North America market dominated the Global Transcatheter Aortic Valve Replacement Market by Region in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $3 billion by 2028. The Europe market is exhibiting a CAGR of 6.8% during (2022 - 2028). Additionally, The Asia Pacific market would showcase a CAGR of 8.5% during (2022 - 2028).
Full Report: https://www.kbvresearch.com/transcatheter-aortic-valve-replacement-market/
The market research report has exhaustive quantitative insights providing a clear picture of the market potential in various segments across the globe with country wise analysis in each discussed region. The key impacting factors of the market have been discussed in the report with the elaborated company profiles of Abbott Laboratories, Medtronic PLC, Boston Scientific Corporation, Edwards Lifesciences Corporation, MicroPort Scientific Corporation, LivaNova PLC, TTK Healthcare Limited, Meril Life Science Private Limited, JenaValve Technology, Inc., and Bracco S.p.A.
By Material
By Implantation Procedure
By Mechanism
By End-use
By Geography
Companies Profiled
Unique Offerings 
